Relation of cyclic guanosine monophosphate and cyclic adenosine monophosphate in reducing the toxic effects of protamine administration.
Katircioğlu
S F
SF
Taşdemir
O
O
Bayazit
K
K
D000818:Animals; D000242:Cyclic AMP / Q000037:antagonists & inhibitors / Q000502:physiology; D006152:Cyclic GMP / Q000037:antagonists & inhibitors / Q000502:physiology; D006493:Heparin / Q000494:pharmacology*; D007022:Hypotension / Q000139:chemically induced* / Q000503:physiopathology; D008955:Models, Cardiovascular; D009200:Myocardial Contraction / Q000187:drug effects* / Q000502:physiology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D011479:Protamines / Q000494:pharmacology*; D011817:Rabbits
D011479:Protamines; D009569:Nitric Oxide; D006493:Heparin; D000242:Cyclic AMP; D006152:Cyclic GMP